You are here

Share:

Search Technologies

Showing 1-20 of 67 results found

Zirconium-89 PET Imaging Agent for Cancer

This technology is a new generation of rationally designed chelating agents that improve the complexation of Zirconium-89 for PET imaging of cancers.

Urine-based Diagnostic Assay for the Early Detection of Cancer

Researchers at the NCI have developed a urine-based diagnostic platform capable of predicting the onset of cancer. This high-throughput screening method quantifies metabolites to assess cancer risk, determine disease prognosis and monitor response to therapy.

The Biospecimen Pre-analytical Variables (BPV) Program

The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.

SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer

This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic DNA obtained from a blood sample to predict survival from diagnosis of prostate cancer in that individual patient.

Reporter Plasmid to Identify Cancer Stem Cells

The National Cancer Institute’s Laboratory of Cancer Biology and Genetics seeks partners to co-develop lentiviral plasmids, a research tool for visualizing and purifying cancer stem cells.

Ratio Based Biomarkers for the Prediction of Cancer Survival

The NCI seeks licensees or co-development partners for this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.

Quantitative In Vivo Methods for Measuring Brain Networks

Researchers at the NICHD seek licensing and/or co-development research collaborations for a Magnetic Resonance Imaging (MRI) method to quantitatively measure in vivo the estimated conduction time of nerve impulses in the brain.

Prognostic Biomarkers for Patients with Early Stage Lung Cancer

Investigators at the National Cancer Institute discovered a set of biomarkers that can identify patients with early stage lung cancer who are at a high risk of relapse. These prognostic methods can guide physicians to select appropriate treatment and follow-up while sparing other patients of unnecessary treatment and negative side-effects of chemotherapy. The NCI seeks parties to license or co-develop the invention.

Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue

Researchers in the National Cancer Institute’s Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. NCI seeks partners to license this technology.

Non-invasive Methods for Characterizing Adrenocortical Tumors

Researchers at the NCI developed a non-invasive method for distinguishing benign from malignant adrenocortical tumors using urine samples. The NCI seeks parties to co-develop a non-invasive, diagnostic method of distinguishing between benign and malignant adrenocortical tumors through the analysis of metabolites using urine samples.

Non-Invasive In Vivo MRI Method to Image Salient Features of Axons and Nerves

Scientists from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have developed a novel diffusion Magnetic Resonance Imaging (MRI) experimental and modeling framework to measure new and useful microanatomical features of white matter (and gray matter), which are closely related to the function of the central nervous system (CNS) or peripheral nervous system (PNS). This invention is available for licensing or co-development partners.

Non-invasive diagnostic and prognostic assay for early stage lung cancer

NCI scientists developed a method that uses urine samples to detect early-stage cancers and that could supplement low-dose computed tomography (LD-CT) to significantly decrease its expensive false negative/false positive results, and the NCI seeks co-developers or licensees to commercialize this technology.

Pages